Overview of adjunctive hyperbaric oxygen therapy for diabetic foot ulcer
Hailey D, Jacobs P, Perry DC, Chuck A, Morrison A, Boudreau R
Record ID 32007000121
English
Authors' objectives:
This study examines the use of adjunctive hyperbaric oxygen therapy (HBOT) for diabetic foot ulcer (DFU), acomplication of diabetes mellitus, in adults and children.
Authors' recommendations:
Implications for Decision Making
Adjunctive HBOT for DFU is moreeffective than standard care alone. The proportion of major LEAs can decrease from32% among patients receiving standard careto 11% among those receiving adjunctive HBOT. There was a decrease in the proportion of unhealed wounds with HBOT; the reverse was true for minor LEAs.
HBOT for DFU is cost effective compared with standard care. The 12-year cost for a patient receiving HBOT was 40,695 Canadian dollars compared to 49,786 Canadian dollarsfor standard care alone,with an associated increase of 0.63 quality adjusted life years (QALYs) (3.01 QALYs forstandard care to 3.64 QALYs for those receiving HBOT).
HBOT requires additional resources and planning. The estimated costs to treat all prevalent DFU cases in Canada is 14 million Canadian dollars per year for four years. An estimated 179 additional monoplace chambers or 19 seven-person multiplace HBOT chambers would be required.
Optimal use will require additional considerations. Guidelines would need to be applied to identify those patients most appropriately treated with HBOT. As standard care evolves and better quality studies become available, the estimated comparative advantage of HBOT may change.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Diabetic Foot
- Hyperbaric Oxygenation
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.